| Raiz Invest Limited (RZI) ORDINARY FULLY PAID |
Financials |
$73 |
Raiz Share Purchase Plan
|
30 Aug 2024 9:27AM |
$0.400 |
$0.695 |
risen by
73.75%
|
|
RZI - Price-sensitive ASX Announcement
Full Release
Key Points
- Raiz Invest Limited announced a Share Purchase Plan (SPP) to allow eligible shareholders to purchase up to $30,000 of new shares without incurring brokerage or other transaction costs.
- The SPP aims to raise up to $2 million and follows the successful institutional placements which raised $3 million.
- New SPP shares are offered at the lower of $0.41 per share or a 2.5% discount to the volume-weighted average price (VWAP) of Raiz Invest shares traded on ASX during the five trading days up to the SPP closing date.
- The proceeds from the SPP will be used for strategic opportunities, including building a bespoke AI language model, product innovation, and potential future mergers and acquisitions.
- Participation in the SPP is voluntary and is available to shareholders with addresses in Australia or New Zealand who held shares as of 23 August 2024.
- Shares issued under the SPP will rank equally with existing shares.
- The SPP is not available to shareholders in the United States or those holding shares on behalf of persons in the United States.
- Applications for the SPP must be received by 5:00pm on 13 September 2024, and shares will be issued on 20 September 2024.
- Raiz Invest reserves the right to scale back applications and any oversubscription funds will be refunded.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| LTR Pharma Ltd (LTP) ORDINARY FULLY PAID |
Health Care |
$35 |
Appendix 4E and Annual Financial Report
|
30 Aug 2024 9:27AM |
$1.770 |
$0.310 |
fallen by
82.49%
|
|
LTP - Price-sensitive ASX Announcement
Full Release
Key Points
- LTR Pharma Limited successfully completed an IPO and listed on the Australian Securities Exchange under the ticker ASX: LTP in December 2023.
- The company's flagship product, SPONTAN, is an innovative nasal spray treatment for Erectile Dysfunction (ED) designed to work within 10 minutes.
- SPONTAN has demonstrated a significant improvement over oral treatments in clinical studies, achieving maximum concentration levels in an average of 12 minutes.
- LTR Pharma's financial results for the year ended 30 June 2024 show a significant increase in revenue but also a substantial net loss.
- The company raised $7 million through its IPO to support R&D activities and the commercialisation pathway of SPONTAN.
- LTR Pharma completed its pivotal pharmacokinetic clinical study for SPONTAN, showing rapid absorption and faster onset of action compared to oral PDE5 inhibitors.
- The company achieved manufacturing validation for SPONTAN, meeting essential FDA requirements for a pivotal clinical study.
- LTR Pharma's Chief Scientific Advisor, Professor Eric Chung, was awarded the ISSM Emil Tanagho Prize for innovative research in ED treatments.
- The company's net tangible asset per ordinary share increased from 1.487 cents in 2023 to 2.109 cents in 2024.
- LTR Pharma completed a $10.5 million share placement and signed a Global Co-Development agreement post the financial year-end.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Livium Ltd (LIT) ORDINARY FULLY PAID |
Industrials |
$17 |
Sustainability Report
|
30 Aug 2024 9:26AM |
$0.021 |
$0.010 |
fallen by
52.38%
|
|
| Future Generation Global Limited (FGG) ORDINARY FULLY PAID |
Financials |
$575 |
Appendix 4D and Financial Report
|
30 Aug 2024 9:25AM |
$1.330 |
$1.440 |
risen by
8.27%
|
|
FGG - Price-sensitive ASX Announcement
Full Release
Key Points
- True and fair view of the company’s financial position as at 30 June 2024.
- Compliance with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001.
- Review conducted in accordance with ASRE 2410 Review of a Financial Report Performed by the Independent Auditor.
- Independence of the Company in accordance with the auditor independence requirements of the Corporations Act 2001.
- Directors are responsible for the preparation of the half-year financial report.
- Total comprehensive income for the period ended 30 June 2024.
- Financial performance overview includes trading revenue, cost of sales, gross profit, and other income and expenses.
- Balance sheet items cover working capital, property, plant and equipment, and provisions.
- Capital structure and risk management include credit facilities, issued capital, and financial risk management.
- Group structure details subsidiaries, deed of cross guarantee, and non-controlling interests.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ImExHS Limited (IME) ORDINARY FULLY PAID |
Health Care |
$17 |
Investor Presentation - 1H FY24 Results
|
30 Aug 2024 9:24AM |
$0.500 |
$0.330 |
fallen by
34%
|
|
IME - Price-sensitive ASX Announcement
Full Release
Key Points
- 1H FY24 Underlying EBITDA of $0.3m, down $0.2m vs pcp
- 1H FY24 Revenue of $13.8m, 57% up on pcp and 32% up on constant currency
- Annualised Recurring Revenue of $29.6m, up 21% vs pcp
- Significant working capital consumption with net cash used in operating activities of $1.5m
- Enterprise software contract renewal with Colsubsidio contributing $575,000 in ARR
- New contract in Colombia valued at $790,000 for biomedical equipment and AQUILA Enterprise
- Strong sales pipeline for IMEXHS Cloud and Enterprise radiology solutions
- Software development program on time and on budget
- Radiology profit improvement through renegotiation of contracts
- New radiology services contract in Colombia with expected ARR of $564,000
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| FBR Ltd (FBR) ORDINARY FULLY PAID |
Industrials |
$34 |
Preliminary Final Report
|
30 Aug 2024 9:24AM |
$0.037 |
$0.006 |
fallen by
83.78%
|
|
FBR - Price-sensitive ASX Announcement
Full Release
Key Points
- FBR Ltd released its Preliminary Final Report for the financial year.
- Revenue for the year was $1.67 million, compared to $1.09 million in the previous year.
- Net loss after tax was $9.59 million, compared to $5.12 million in the previous year.
- Total comprehensive loss for the year was $9.47 million.
- Cash and cash equivalents at year-end were $3.76 million.
- The company focused on commercialization of its Hadrian X technology.
- Significant progress was made in the construction and application of Hadrian X for bricklaying.
- FBR Ltd has engaged in several partnerships and pilot programs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Complii Fintech Solutions Ltd (CF1) ORDINARY FULLY PAID |
Information Technology |
$13 |
Issue of Shares
|
30 Aug 2024 9:24AM |
$0.023 |
$0.023 |
fallen by
0%
|
|
| Swift Networks Group Limited (SW1) ORDINARY FULLY PAID |
Communication Services |
$9 |
Annual Results Presentation
|
30 Aug 2024 9:24AM |
$0.015 |
$0.010 |
fallen by
33.33%
|
|
SW1 - Price-sensitive ASX Announcement
Full Release
Key Points
- $2.4 million Enterprise EBITDA
- $15.0 million annualised Subscription Revenue
- Generating cash from operations
- Low market cap – 50% of Revenue
- Turn-around story
- Inhouse development team
- Aged Care market has strong growth
- Enviable customer base (path to market)
- New SaaS product under development
- New Platform/Tech brings access to new aligned markets
- Worldwide market opportunities for Swift Access Engagement SaaS
- Swift Networks Group Limited operates in the Aged Care and Mining sectors
- Capital Structure with 647 million shares on issue
- Market Capitalisation of $9.7 million
- Debt of $7.4 million as of 30 June 2024
- Major shareholders include Sofoulis Holdings Pty Ltd and JP Morgan Nominees Australia Pty Ltd
- Goals include growing subscription earnings, securing large provider Aged Care subscription contracts, and launching Swift Access into new markets
- Swift Access Aged Care Engagement (ACE) product to be launched in Australian Aged Care in 2024
- Strong growth potential in Mining and Aged Care sectors
- Focus on reducing debt and improving margins
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ImExHS Limited (IME) ORDINARY FULLY PAID |
Health Care |
$17 |
IMEXHS Reports 1H FY24 Results
|
30 Aug 2024 9:23AM |
$0.500 |
$0.330 |
fallen by
34%
|
|
IME - Price-sensitive ASX Announcement
Full Release
Key Points
- 1HFY24 revenue of $13.8m, up 57% vs pcp; up 32% on a constant currency basis.
- 1HFY24 Underlying EBITDA of $0.3m; down 47% vs pcp.
- Annualised Recurring Revenue (ARR) of $29.6m, up 21% vs pcp.
- Debt of $0.9m at 30 June 2024, down from $1.3m at 31 Dec 2023.
- Cash of $1.9m at 30 June 2024, down from $2.4m at 31 Dec 2023.
- Enterprise software contract renewal with Colsubsidio, expected to contribute $575,000 in ARR.
- New one-off contract secured in Colombia for $790,000.
- New radiology services contract in Colombia, expected to contribute $564,000 in ARR.
- Sales pipeline for both IMEXHS Software and Radiology services remains strong.
- IMEXHS Enterprise and Cloud have a total of 518 installations worldwide.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Complii Fintech Solutions Ltd (CF1) ORDINARY FULLY PAID |
Information Technology |
$13 |
Application for quotation of securities - CF1
|
30 Aug 2024 9:23AM |
$0.023 |
$0.023 |
fallen by
0%
|
|
| Hubify Limited (HFY) ORDINARY FULLY PAID |
Communication Services |
$4 |
Notification of cessation of securities - HFY
|
30 Aug 2024 9:23AM |
$0.012 |
$0.008 |
fallen by
33.33%
|
|
| WCM Quality Global Growth Fund (Managed Fund) (WCMQ) |
Financials |
$400 |
Quarterly portfolio disclosure as at 30 June 2024
|
30 Aug 2024 9:22AM |
$8.700 |
$11.050 |
risen by
27.01%
|
|
| EDU Holdings Limited (EDU) ORDINARY FULLY PAID |
Consumer Discretionary |
$25 |
1H24 - Half-Year Results Presentation
|
30 Aug 2024 9:22AM |
$0.090 |
$0.165 |
risen by
83.33%
|
|
EDU - Price-sensitive ASX Announcement
Full Release
Key Points
- Group revenue increased by 64% with Ikon up 88% and ALG up 37%
- EBITDA improved significantly to $2.3 million from $0.2 million
- Statutory net profit after tax was $28,000, an improvement of $1.6 million
- Ikon enrolments grew by 85% and continued growth into Trimester 2, 2024
- ALG enrolments rebounded with a 24% increase in 1H24
- Operating leverage was evident with an 8 percentage points improvement in EBITDA margin
- Strategic positioning in response to regulatory changes likely to affect future enrolments
- Strong cash balance with net cash increasing by $5.2 million to $6.3 million
- Focus on student volume growth, product development, operational efficiency, and preparation for proposed caps on new overseas student commencements
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Chariot Corporation Ltd (CC9) ORDINARY FULLY PAID |
Materials |
$9 |
Chariot & Mustang Lithium LLC Update
|
30 Aug 2024 9:22AM |
$0.105 |
$0.078 |
fallen by
25.71%
|
|
CC9 - Price-sensitive ASX Announcement
Full Release
Key Points
- Chariot holds a 24.1% ownership interest in Mustang Lithium LLC.
- Mustang is repossessing the Horizon and Halo lithium projects.
- Pan American Energy Corp. and POWR Lithium Corp. terminated their property option agreements due to market conditions.
- Mustang raised USD 250,000 through convertible notes for maintenance fees.
- Horizon Lithium Project has an Indicated category of 1.3 Mt LCE and an Inferred category of 8.8 Mt LCE.
- Chariot’s core projects include Black Mountain and Resurgent Projects.
- Chariot holds interests in multiple exploration pipeline projects in Wyoming and Nevada.
- Property option agreements with Pan American Energy and POWR are being terminated.
- Pan American Energy reported a maiden Mineral Resource estimate for Horizon Lithium Project.
- Mustang's liquid assets include shares in Pan American Energy, POWR, and other companies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Resonance Health Limited (RHT) ORDINARY FULLY PAID |
Health Care |
$17 |
Appendix 4E & Annual Report to Shareholders
|
30 Aug 2024 9:22AM |
$0.052 |
$0.037 |
fallen by
28.85%
|
|
RHT - Price-sensitive ASX Announcement
Full Release
Key Points
- Resonance Health Limited is an Australian healthcare technology and services company.
- The company provides quantitative imaging assessments globally for disease management and clinical trials.
- Record revenues of $8.6M in FY24, a 95% increase from FY23.
- Significant clinical trial contract worth $6.33M with a major global pharma company.
- Acquisition of TrialsWest, a clinical research center.
- Development of non-invasive MRI liver fibrosis assessment tool.
- Strong performance in North America, Asia Pacific, and the UK.
- Expansion into the clinical trial ecosystem with CRO services.
- No dividends were paid, recommended, or declared during the financial years.
- Positive operating cash flow of $1.39M up from a loss in FY23.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ImExHS Limited (IME) ORDINARY FULLY PAID |
Health Care |
$17 |
Half Yearly Report and Accounts
|
30 Aug 2024 9:22AM |
$0.500 |
$0.330 |
fallen by
34%
|
|
IME - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from ordinary activities increased by 56.6% to $13,784,973.
- Loss after tax decreased by 33.8% to $1,518,459.
- No dividends were paid, recommended, or declared.
- Net tangible assets per ordinary security were 15.26 cents, down from 20.25 cents.
- Joint operation entered on 24 August 2023 with a 75% interest for radiology services with Colombia's National Police Hospital.
- Unmodified audit opinion with emphasis on going concern issued.
- Group’s EBITDA was a profit of $0.03m compared to EBITDA loss of $1.0m for 1H FY23.
- ARR of $29.6m as at 30 June 2024, up 21% vs pcp.
- Significant revenue growth in both software and radiology services segments.
- Revenue growth was driven by recurring revenue contracts accounting for 95% of revenue.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Livium Ltd (LIT) ORDINARY FULLY PAID |
Industrials |
$17 |
Corporate Governance Statement
|
30 Aug 2024 9:21AM |
$0.021 |
$0.010 |
fallen by
52.38%
|
|
| Complii Fintech Solutions Ltd (CF1) ORDINARY FULLY PAID |
Information Technology |
$13 |
Application for quotation of securities - CF1
|
30 Aug 2024 9:21AM |
$0.023 |
$0.023 |
fallen by
0%
|
|
| IRIS Metals Limited (IR1) ORDINARY FULLY PAID |
Materials |
$22 |
AGM Chair Address
|
30 Aug 2024 9:20AM |
$0.180 |
$0.125 |
fallen by
30.56%
|
|
| Global X Nasdaq 100 Covered Call ETF (QYLD) |
Financials |
$17 |
Global X Updated Est. Distribution Announcement - Aug 2024
|
30 Aug 2024 9:20AM |
$11.040 |
$10.960 |
fallen by
0.72%
|
|
| Global X S&P 500 Covered Call ETF (UYLD) |
Financials |
$8 |
Global X Updated Est. Distribution Announcement - Aug 2024
|
30 Aug 2024 9:20AM |
$10.710 |
$10.960 |
risen by
2.33%
|
|
| BASKET WARRANTS OVER BANK SHARES (BAN) BASKET WARRANTS OVER BANK SHARES |
- |
|
Global X Updated Est. Distribution Announcement - Aug 2024
|
30 Aug 2024 9:20AM |
$803.510 |
$803.510 |
fallen by
0%
|
|
BAN - Price-sensitive ASX Announcement
Full Release
Key Points
- Global X Management (AUS) Limited announced updated estimated distribution amounts for funds quoted on the AQUA Market for the ASX ending 30 August 2024.
- The ASX Code for the funds involved are BANK, QYLD, and UYLD.
- Distribution amounts per unit are 2.345103 cents for BANK, 8.733262 cents for QYLD, and 5.439203 cents for UYLD.
- The distribution timetable includes key dates such as the Estimated Distribution Announcement Date on 22 August 2024 and the Payment Date on 16 September 2024.
- Investors should consider the relevant product disclosure statement for any potential investment including the risks identified therein.
- Investments in Global X products are subject to investment risks including possible delays in repayment and loss of income and principal invested.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Switzer Dividend Growth Fund (Managed Fund) (SWTZ) |
Financials |
$59 |
Quarterly portfolio disclosure as at 30 June 2024
|
30 Aug 2024 9:20AM |
$2.500 |
$2.390 |
fallen by
4.40%
|
|
| Articore Group Limited (ATG) ORDINARY FULLY PAID |
Consumer Discretionary |
$43 |
Update - Notification of buy-back - ATG
|
30 Aug 2024 9:20AM |
$0.380 |
$0.153 |
fallen by
59.87%
|
|
| Australian Unity Office Property Fund (AOF) ORDINARY UNITS FULLY PAID |
Real Estate |
$80 |
AOF Fund Manager
|
30 Aug 2024 9:20AM |
$1.240 |
$0.485 |
fallen by
60.89%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
